Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-56

I must say I'm a little confused… we get the news that IMU share holders have been waiting for…!!

""Medical researchers observed no safety issues and showed increase of antibody levels at all dose levels and thestudy Cohort Review Committee (CRC) selected the recommended Phase 2 dose (RP2D). ""
&
""Imugene’s Managing Director and Chief Executive Officer Leslie Chong said, “Clinicians at the trial sites observedno vaccine-related toxicities at any of the three doses. We are encouraged by the fact that all vaccinated patientsdeveloped increased antibody levels to the HER-2 target protein. ""

No toxicity, even at high dosage rates....

Herceptin & Perjeta Both had toxicity problems yet they are still use very today. And the share price stays the same or even goes backwards....Very strange.

“We look forward to reporting the top-line results before the end of the year and starting the Phase 2 randomisedtrial early in 2019.”

I will continue to buy more and more at this price.